Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Crescent Biopharma, Inc. - Common Stock (NQ:CBIO)

13.51 +1.01 (+8.08%)
Official Closing Price Updated: 4:15 PM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Crescent Biopharma, Inc. - Common Stock

News headline image
Crescent Biopharma Announces Regulatory Clearances of IND Applications for CR-001, a PD-1 x VEGF Bispecific Antibody and CR-003, an ITGB6-targeted ADC, for the Treatment of Solid Tumors
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Transformational Partnership with Kelun-Biotech and $185 Million Private Placement, Accelerating and Expanding Global Pipeline of Next Generation Therapeutics for Solid Tumors
From Crescent Biopharma, Inc.
Via GlobeNewswire
News headline image
Kelun-Biotech and Crescent Biopharma Announce Strategic Partnership to Develop and Commercialize Novel Oncology Therapeutics
From Crescent Biopharma, Inc.; Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Via GlobeNewswire
News headline image
Crescent Biopharma Announces Grants of Inducement Awards
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at November Investor Conferences
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma to Present at September Investor Conferences
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Crescent Biopharma
Via GlobeNewswire
News headline image
Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer
From Crescent Biopharma
Via GlobeNewswire
News headline image
CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Catalyst Biosciences, Inc. - CBIO
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
CATALYST BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Catalyst Biosciences, Inc. - CBIO
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
CBIO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Catalyst Biosciences, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
JDS1, LLC Terminates Proxy Contest at Catalyst’s 2022 Annual Meeting
From JDS1, LLC
Via Business Wire
News headline image
JDS1, LLC Files Definitive Proxy Statement and Sends Letter to Catalyst Stockholders
From JDS1, LLC
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.